Its restricted occurrence makes BRAFV600E of clinical diagnostic utility (Xing, 2007; Zatelli
et al., 2009). Its carcinogenetic potential has been demonstrated in several different cell …

The BRAFV600E mutation, resulting from a T1799A transversion nucleotide change in the
BRAF gene, was discovered in papillary thyroid cancer (PTC) initially in 2003 (1). Many …

Papillary thyroid carcinomas (PTCs) account for 90% of human thyroid cancer cases, which
represent 1% of all cancer cases. They are likely to develop from papillary thyroid …

The mutant BRAF (BRAFV600E) is the most common genetic alteration in papillary thyroid
carcinomas (PTCs). The oncogenicity of this mutation has been shown by some genetically …

Abstract Context: Although the BRAF V600E mutant can initiate the formation of papillary
thyroid cancer (PTC), it is unclear whether it is required to maintain cell proliferation …

Thyroid cancers stand out among solid tumours because many of the tumour-initiating
genetic events have been identified. Mutations leading to constitutive activation of MAP …

Activating mutations of BRAF have been identified in a variety of human cancers, most
notably melanomas and papillary thyroid carcinomas (PTCs). The aim of the present study …

The BRAFT1799A mutation is the most common genetic alteration in papillary thyroid
carcinomas (PTC). It is also found in a subset of papillary microcarcinomas, consistent with a …

The activating mutation BRAF T1796A is the most prevalent genetic alteration in papillary
thyroid carcinomas (PTC). It is associated with advanced PTCs, suggesting that this …

Differentiated thyroid cancers (papillary-PTC and follicular-FTC) are the most common
endocrine malignancies. The recent progresses in the understanding of PTC and FTC …